Well, that was a weight off my chest, better out than in, as they say. After Brexit, at least the world will be pulled back into its axis with the election of America’s first woman president and wait a minute, what are you saying? No, that can’t be right he won? Really? REALLY?
Neovacs teams up with 3P
Latest NewsFrench immunotherapy expert Neovacs has teamed up with CDMO 3P Biopharmaceuticals for the manufacture of interferon alpha with recently licensed technology.
Kymab raises €94m for mAb pipeline
Latest NewsUK-based biopharma group Kymab has brought a new backer from China on board. With the help from ORI Healthcare Fund, Kymab secured a US$100m Series C financing.
From randomised and controlled to clinical reality
OpinionThe randomised clinical trial (RCT) is the gold standard for drug evaluation. RCTs provide the core for drug development and subsequent drug approval often in the form of rigorously designed efficacy trials in carefully selected subjects. In fact, in- and exclusion criteria are often so restrictive that only 17% of patients from outpatient clinics would be eligible for trials in asthma and chronic obstructive pulmonary disease (COPD).
And the world turns
OpinionWell, that was a weight off my chest, better out than in, as they say. After Brexit, at least the world will be pulled back into its axis with the election of America’s first woman president and wait a minute, what are you saying? No, that can’t be right he won? Really? REALLY?
Proteros inks US$167m oncology pact with MSD
Latest NewsProteros has expanded its epigenetic drug discovery services for MSD. Just one year after having signed a first R&D pact, the computational chemistry firm inked a second contract in oncology.
Running made by biotech
Latest NewsAdidas has presented the world’s first lightweight racing shoe made by recombinantly produced silk fibers.
Acesion Pharma: New head of finance
AppointmentsPharmaMar: Pushing the borders
AppointmentsBIA: Three new faces on the board
AppointmentsMedigene offers neoantigen-specific TCRs
Latest NewsUntil mid-October, cancer immunotherapy play Medigene AG was a pure drug developer. With a potential US$1bn TCR-contract manufacturing deal with Bluebird Bio, it widened its business focus. Now, the company presented a process that delivers neospecific anti-tumour TCRs.